Rodney Rouse

Dr. Rodney Rouse


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2020 in BMC Genomics
Verified
Journal Article
Open access
PDF file
LXLei Xu
Lei Xu
ASAnil Surathu
Anil Surathu
IRIsaac Raplee
Isaac Raplee
ACAshok Chockalingam
Ashok Chockalingam
SSSharron Stewart
Sharron Stewart
RRRodney Rouse
Rodney Rouse
Background: Emergence of antibiotic resistance is a global public health concern. The relationships between antibiotic use, the gut community composition, normal physiology and metabolism, and individual and public health are still being defined. Shifts in composition of bacteria, antibiotic resistance genes (ARGs) and mobile genetic elements (MGEs) after antibiotic treatment are not well-understood. Methods: This project used next-generation sequencing, custom-built metagenomics pipeline and differential abundance analysis to study the effect of antibiotic monotherapy on resistome and taxonomic composition in the gut of Balb/c mice infected with E. coli via transurethral catheterization to investigate the evolution and emergence of antibiotic resistance. Results: There is a longitudinal decrease of gut microbiota diversity after antibiotic treatment. Various ARGs are enriched within the gut microbiota despite an overall reduction of the diversity and total amount of bacteria after antibiotic treatment. Sometimes treatment with a specific class of antibiotics selected for ARGs that resist antibiotics of a completely different class (e.g. treatment of ciprofloxacin or fosfomycin selected for cepA that resists ampicillin). Relative abundance of some MGEs increased substantially after antibiotic treatment (e.g. transposases in the ciprofloxacin group). Conclusions: Antibiotic treatment caused a remarkable reduction in diversity of gut bacterial microbiota but enrichment of certain types of ARGs and MGEs. These results demonstrate an emergence of cross-resistance as well as a profound change in the gut resistome following oral treatment of antibiotics.

1 June 2011 in Kidney International
Verified
Journal Article
Closed access
RRRodney Rouse
Rodney Rouse
JZJun Zhang
Jun Zhang
SSSharron R. Stewart
Sharron R. Stewart
BRBarry A. Rosenzweig
Barry A. Rosenzweig
PEParvaneh Espandiari
Parvaneh Espandiari
NSNakissa K. Sadrieh
Nakissa K. Sadrieh

1 March 2018 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Open access
PDF file
RRRodney Rouse
Rodney Rouse
NKNaomi Kruhlak
Naomi Kruhlak
JWJames Weaver
James Weaver
KBKeith Burkhart
Keith Burkhart
VPVikram Patel
Vikram Patel
DSDavid G. Strauss
David G. Strauss
In 2011, the US Food and drug Administration (FDA) developed a strategic plan for regulatory science that focuses on developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of FDA-regulated products. In line with this, the Division of Applied Regulatory Science was created to move new science into the Center for Drug Evaluation and Research (CDER) review process and close the gap between scientific innovation and drug review. The Division, located in the Office of Clinical Pharmacology, is unique in that it performs mission-critical applied research and review across the translational research spectrum including in vitro and in vivo laboratory research, in silico computational modeling and informatics, and integrated clinical research covering clinical pharmacology, experimental medicine, and postmarket analyses. The Division collaborates with Offices throughout CDER, across the FDA, other government agencies, academia, and industry. The Division is able to rapidly form interdisciplinary teams of pharmacologists, biologists, chemists, computational scientists, and clinicians to respond to challenging regulatory questions for specific review issues and for longer-range projects requiring the development of predictive models, tools, and biomarkers to speed the development and regulatory evaluation of safe and effective drugs. This article reviews the Division’s recent work and future directions, highlighting development and validation of biomarkers; novel humanized animal models; translational predictive safety combining in vitro, in silico, and in vivo clinical biomarkers; chemical and biomedical informatics tools for safety predictions; novel approaches to speed the development of complex generic drugs, biosimilars, and antibiotics; and precision medicine.

17 July 2017 in Particle and Fibre Toxicology
Verified
Journal Article
Open access
PDF file
JWJames L. Weaver
James L. Weaver
GTGrainne A. Tobin
Grainne A. Tobin
TITaylor Ingle
Taylor Ingle
SBSimona Bancos
Simona Bancos
DSDavid Stevens
David Stevens
KTKatherine M. Tyner
Katherine M. Tyner
As nanoparticles (NPs) become more prevalent in the pharmaceutical industry, questions have arisen from both industry and regulatory stakeholders about the long term effects of these materials. This study was designed to evaluate whether gold (10 nm), silver (50 nm), or silica (10 nm) nanoparticles administered intravenously to mice for up to 8 weeks at doses known to be sub-toxic (non-toxic at single acute or repeat dosing levels) and clinically relevant could produce significant bioaccumulation in liver and spleen macrophages. Repeated dosing with gold, silver, and silica nanoparticles did not saturate bioaccumulation in liver or spleen macrophages. While no toxicity was observed with gold and silver nanoparticles throughout the 8 week experiment, some effects including histopathological and serum chemistry changes were observed with silica nanoparticles starting at week 3. No major changes in the splenocyte population were observed during the study for any of the nanoparticles tested. The clinical impact of these changes is unclear but suggests that the mononuclear phagocytic system is able to handle repeated doses of nanoparticles.

1 April 2014 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
RRRodney Rouse
Rodney Rouse
LXLin Xu
Lin Xu
SSSharron Stewart
Sharron Stewart
JZJun Zhang
Jun Zhang

28 September 2019 in Antibiotics
Verified
Journal Article
Open access
PDF file
ACAshok Chockalingam
Ashok Chockalingam
SSSharron Stewart
Sharron Stewart
LXLin Xu
Lin Xu
AGAdarsh Gandhi
Adarsh Gandhi
MMMurali Matta
Murali Matta
RRRodney Rouse
Rodney Rouse
Urinary tract infections (UTI) are common worldwide and are becoming increasingly difficult to treat because of the development of antibiotic resistance. Immunocompetent murine models of human UTI have been used to study pathogenesis and treatment but not for investigating resistance development after treatment with antibiotics. In this study, intravesical inoculation of uropathogenic Escherichia coli CFT073 in immunocompetent Balb/c mice was used as a model of human UTI. The value of the model in investigating antibiotic exposure on in vivo emergence of antibiotic resistance was examined. Experimentally infected mice were treated with 20 or 200 mg/kg ampicillin, 5 or 50 mg/kg ciprofloxacin, or 100 or 1000 mg/kg of fosfomycin. Ampicillin and ciprofloxacin were given twice daily at 8 h intervals, and fosfomycin was given once daily. Antibiotic treatment began 24 h after bacterial inoculation and ended after 72 h following the initial treatment. Although minimum inhibitory concentrations (MIC) for the experimental strain of E. coli were exceeded at peak concentrations in tissues and consistently in urine, low levels of bacteria persisted in tissues in all experiments. E. coli from bladder tissue, kidney, and urine grew on plates containing 1× MIC of antibiotic, but none grew at 3× MIC. This model is not suitable for studying emergent resistance but might serve to examine bacterial persistence.